Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.50 |
| ▸ | HTR2C | P28335 | 8/20 | 0.49 |
| ▸ | QDPR | P09417 | 2/20 | 0.48 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.46 |
| ▸ | NAMPT | P43490 | 1/20 | 0.42 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.40 |
| ▸ | CDK9 | P50750 | 1/20 | 0.40 |
| ▸ | RAD52 | P43351 | 1/20 | 0.39 |
| ▸ | UBE2N | P61088 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | FTO | Q9C0B1 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12193536 | 0.86 | SIGMAR1 (0.61) | SIGMAR1HTR2CQDPRNAMPT | |
| Trifluoroacetic Acid SCHEMBL19989664 | 0.85 | SIGMAR1 (0.67) | SIGMAR1HTR2CQDPRP2RY14NAMPT | |
| Hydrochloric Acid SCHEMBL18113481 | 0.84 | HTR2C (0.62) | SIGMAR1HTR2CQDPRNAMPT | |
| Trifluoroacetic Acid SCHEMBL16228956 | 0.83 | SIGMAR1 (0.51) | SIGMAR1HTR2CQDPRP2RY14NAMPT | |
| Trifluoroacetic Acid SCHEMBL9023698 | 0.82 | SIGMAR1 (0.46) | SIGMAR1HTR2CQDPRP2RY14NAMPT | |
| Trifluoroacetic Acid SCHEMBL29749858 | 0.81 | QDPR (0.50) | SIGMAR1HTR2CQDPRP2RY14NAMPT | |
| Trifluoroacetic Acid SCHEMBL16799644 | 0.81 | HTR2C (0.71) | SIGMAR1HTR2CQDPRP2RY14NAMPT | |
| Trifluoroacetic Acid SCHEMBL30182435 | 0.81 | QDPR (0.53) | SIGMAR1HTR2CQDPRP2RY14NAMPT | |
| Trifluoroacetic Acid SCHEMBL3854727 | 0.79 | TRPV1 (0.40) | SIGMAR1HTR2CP2RY14 | |
| Trifluoroacetic Acid SCHEMBL21003196 | 0.76 | P2RY14 (0.37) | SIGMAR1HTR2CQDPRP2RY14CCNT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8546404-B2 | Compounds that are ERK inhibitors | MERCK SHARP & DOHME (US) | 2013-10-01 | — | — | US | disclosed |
| EP-1966151-B1 | POLYCYCLIC INDAZOLE DERIVATIVES THAT ARE ERK INHIBITORS | SCHERING CORP (US) | 2011-10-05 | — | — | EP | disclosed |
| US-20110038876-A1 | HETEROCYCLIC COMPOUNDS AND USE THEREOF AS ERK INHIBITORS | SCHERING CORPORATION | 2011-02-17 | — | — | US | disclosed |
| US-20090118284-A1 | Novel compounds that are ERK inhibitors | MERCK SHARP & DOHME LLC | 2009-05-07 | — | — | US | disclosed |
| US-20070191604-A1 | Novel compounds that are ERK inhibitors | SCHERING CORPORATION | 2007-08-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110038876-A1 | HETEROCYCLIC COMPOUNDS AND USE THEREOF AS ERK INHIBITORS | MAPK1, MAPK4, MAPK10 | SIGMAR1 1550/4885HTR2C 3489/4885QDPR 667/4885 |
| US-20090118284-A1 | Novel compounds that are ERK inhibitors | MAPK1, MAPK4, MAPK10 | SIGMAR1 1543/4885HTR2C 4139/4885QDPR 546/4885 |
| US-20070191604-A1 | Novel compounds that are ERK inhibitors | MAPK1, MAPK4, MAPKAPK2 | SIGMAR1 1454/4885HTR2C 3899/4885QDPR 441/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.